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EXPERT OPINION
Abstract: Generalized anxiety disorder (GAD) is a common, typically persistent, and disabling
condition that is often not recognised, or treated in an evidence-based manner. Current
pharmacological and psychological treatment approaches have a number of drawbacks,
including a delay in onset of clinical effect, varying relative efficacy against psychological or
somatic symptoms of anxiety, potentially troublesome adverse effects, and discontinuation
symptoms on stopping treatment. Pregabalin is a structural analog of the inhibitory
neurotransmitter gamma amino butyric acid (GABA) but is thought to exert its anxiolytic
effects through binding in a state-dependent manner to the alpha-2-delta sub-unit of voltage-
gated calcium channels in “over-excited” pre-synaptic neurones, reducing release of excitatory
neurotransmitters such as glutamate and substance P. At fixed doses of 200 mg/day or greater,
it has consistent proven efficacy in acute treatment of DSM-IV-defined GAD, with some
evidence of an early onset of clinical effect, and of efficacy across psychological and somatic
anxiety symptom clusters. A pregabalin dosage of 450 mg/day is efficacious in the prevention
of relapse. There is at present no published direct comparison with an SSRI. The current
known adverse effect profile and studies in healthy volunteers together suggest that pregabalin
may have some tolerability advantages over benzodiazepines and venlafaxine, at least in
short-term treatment.
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GAD: clinical features, epidemiology and
presumed neuropsychobiology
Generalized anxiety disorder (GAD) is characterized by excessive and inappropriate
worrying that persists (lasting 6 months or more) and is not restricted to particular
circumstances. DSM-IV-TR diagnostic criteria for GAD (APA 2000) require that
anxiety and worry are accompanied by at least 3 of 6 key symptoms (restlessness,
fatigue, difficulty concentrating, irritability, muscle tension, and disturbed sleep).
ICD-10 research diagnostic criteria give greater prominence to the presence of somatic
complaints, and at least one symptom of ‘autonomic arousal’ is essential for diagnosis
(WHO 1994).
However defined, GAD is certainly common: for example, a recent review of
epidemiological studies in Europe reported 12-month and lifetime prevalence
estimates of 1.5% and 5.1%, respectively (Lieb et al 2005). It is among the most
common mental disorders in primary care, and is associated with increased use of
health services; but is often not recognised, possibly because only a minority present
with anxiety symptoms (Ormel et al 1990). Patients with significant co-existing
depressive symptoms have a more severe and persistent course of illness and greater
associated functional impairment (Kessler et al 1999), but a greater chance of being
recognized as having mental health problems (Wittchen et al 2002).
GAD has an uncertain neuropsychobiology. Genetic studies suggest that GAD
and major depression have a common genetic basis, and that environmental factors
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influence their manifestation (Kendler et al 1992). Changes
in serotonin (5-hydroxytryptamine, 5-HT), noradrenaline,
and gamma amino butyric acid (GABA) are probably
important in the treatment response, and disturbances in
these neurotransmitters may underpin the pathophysiology
of the untreated condition. For example, administration of
m-CPP (a non-specific 5HT1 and 5HT2 agonist) has been
found to increase anxiety (Germine et al 1992); blunting of
the growth hormone response to clonidine (an alpha-2
adrenoceptor agonist) suggests decreased alpha-2 adrenergic
receptor sensitivity (Abelson et al 1991); and imaging
studies demonstrate decreased binding of a radiotracer
ligand for GABAA receptors in the left temporal pole
(Tiihonen et al 1997).. Patients show a specific “cognitive
bias” with increased attention to threat-related information
and misinterpretation of ambiguous stimuli as threatening,
and this bias has been shown to diminish with cognitive-
behaviour therapy (CBT) and after selective serotonin
reuptake inhibitor (SSRI) treatment
 (Mogg et al 1995, 2004).
Current treatment approaches in GAD
In acute treatment, systematic reviews and randomized
placebo-controlled trials indicate that CBT, some SSRIs
(escitalopram, paroxetine, and sertraline), some serotonin-
noradrenaline reuptake inhibitors (SNRIs) (duloxetine and
venlafaxine), some benzodiazepines (alprazolam and
diazepam), the 5-HT1A partial agonist buspirone, the
antipsychotic trifluoperazine, and the antihistamine
hydroxyzine are all efficacious (Baldwin et al 2005). Most
comparator-controlled studies reveal no differences in
efficacy between active compounds (Mitte 2005), although
escitalopram appeared superior to paroxetine on some
outcome measures in a recent large multi-centre placebo
controlled study (Baldwin et al 2006), and psychological
symptoms of anxiety are traditionally thought to respond
better to antidepressant drugs than to benzodiazepines
(Baldwin and Polkinghorn 2005).
In longer-term treatment, some randomized controlled
trials indicate that continuing an SSRI or SNRI is associated
with an increase in overall response rates, up to 24 weeks
(Montgomery et al 2002; Bielski et al 2004); and placebo-
controlled relapse prevention studies reveal an advantage
for staying on SSRI treatment, after initial response, for up
to 6 months (Stocchi et al 2003; Allgulander et al 2006).
The comparative efficacy of psychological and
pharmacological treatments is currently uncertain, as is the
advantage or otherwise of combining them together,
compared with either treatment, when given alone. Little is
known about the management of patients with GAD who
do not respond to first-line treatment, although the second-
generation antipsychotic drugs olanzapine and risperidone
have both been found efficacious, in small placebo-
controlled SSRI augmentation studies (Brawman-Mintzer
et al 2005; Pollack et al 2005).
There is still much room for improvement in the
treatment of GAD, as the availability of CBT is restricted
and the “ideal” anxiolytic drug does not yet exist (see Table
1). For example, SSRIs and the SNRI venlafaxine have
proven efficacy in acute and long-term treatment of GAD,
but treatment-emergent adverse effects such as sexual
dysfunction are common, and discontinuation symptoms can
be troublesome with paroxetine and venlafaxine.
Benzodiazepines may promptly reduce symptom severity,
but their limited efficacy in treating depressive symptoms
and associated risks such as drowsiness and the development
of dependence in predisposed individuals lead to
recommendations that they are restricted to patients who
have not responded to other approaches (Bandelow et al
2002; Baldwin et al 2005).
Pregabalin – summary of
pharmacological properties
The mechanism of action of pregabalin (the s-enantiomer
of 3-isobutylgaba) is thought to be different to that of all
other known anxiolytic drugs. Although a structural analog
of the inhibitory neurotransmitter gamma amino butyric acid
(GABA), it has no clinically significant effects at GABAA
or GABAB receptors, and is not converted into either GABA
Table 1 Properties of the “ideal” anxiolytic drug
Effectiveness considerations Acceptability considerations
Effective across full range of anxiety disorders Once-daily dosage
Effective across the spectrum of symptom severity Minimal adverse effects
Effective across age range Minimal interference with everyday life
Effective in achieving remission in acute treatment No development of tolerance
Effective in preventing relapse of symptoms No withdrawal symptoms
Rapid onset of action Suitable in physically ill patients
Effective in treating co-existing depression Free from interactions
Cost-effective Safe in overdoseNeuropsychiatric Disease and Treatment 2007:3(2) 187
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or a GABA agonist. It does not act as an antagonist at
glutamate receptors and has no effects on reuptake of 5-HT
(Kavoussi 2006). Instead, it binds in a state-dependent
manner to the alpha-2-delta sub-unit of voltage-gated
calcium channels of “over-excited” pre-synaptic neurones,
thereby changing the conformation of the channel and
reducing the release of excitatory neurotransmitters such as
glutamate and substance P: the consequent reduced
stimulation of post-synaptic neurones is thought responsible
for its anxiolytic, anticonvulsant, and analgesic effects (Stahl
2004). This proposed mechanism of action is supported by
the findings of pre-clinical studies in animal models, which
indicate that binding to alpha-2-delta receptors is needed
for pregabalin to exert its anxiolytic-like effects (Taylor
2004).
Absorption of pregabalin in the fasting state is rapid,
peak plasma levels occurring within an hour of single or
multiple dosing, steady-state levels being achieved after 24–
48 hours; when given with food, absorption is slower but
its extent is unchanged. It does not bind to plasma proteins,
and being highly lipophilic, readily crosses the “blood–brain
barrier”. Elimination is primarily (92%) through renal
excretion of the parent compound, and dosage therefore
needs to be reduced in patients with renal impairment
(Randinitis et al 2003). The UK Summary of Product
Characteristics (SPC) for pregabalin (May 2006) states that
dosage in patients with compromised renal function must
be individualized according to measured creatinine
clearance. Pregabalin has no active metabolites, does not
inhibit or induce cytochrome (CYP) P450 enzymes, and its
pharmacokinetic properties are not altered by CYP-enzyme
inhibitors.
Efficacy of pregabalin in short-
term and long-term treatment of
GAD
The potential efficacy of pregabalin in DSM-IV defined
GAD was examined through a program of 7 multi-center,
parallel-group, randomized, placebo-controlled trials (see
Table 2). Three initial 4-arm fixed-dose 5-week studies
(comparing pregabalin 150 mg/day or 600 mg/day,
lorazepam 6 mg/day, vs placebo) produced mixed results
on the primary outcome measure, namely change from
baseline to study end-point in mean total score on the
Hamilton Rating Scale for Anxiety (HAM-A) (Hamilton
1959). In one study (Pande et al 2003) (n=276), the
intention-to-treat, last-observation-carried-forward analysis
(ITT, LOCF) indicated that both doses of pregabalin and
lorazepam were superior to placebo, the change in HAMA
score being –9.2 (p<0.05) and –10.3 (p<0.01) with
pregabalin 150 mg/day and 600 mg/day, respectively, and –
12.0 with lorazepam (p<0.001), compared with –6.8 with
placebo. In a second study (Pande et al 2000), neither
pregabalin nor lorazepam were significantly superior to
placebo. In the third (Feltner et al 2003) (n=271), both
pregabalin 600 mg/day (p<0.01) and lorazepam (p<0.05)
were superior to placebo, whereas pregabalin 150 mg/day
was not, the change in HAMA scores being –13.2
(pregabalin 600 mg/day) and –11.6 (lorazepam), compared
with –9.3 with placebo.
The two positive studies are supported by the findings
of 2 further multi-center, parallel-group, randomized,
placebo-controlled trials, in which the efficacy of fixed doses
of pregabalin was compared with that of alprazolam or
venlafaxine (immediate-release formulation). The first
(Rickels et al 2005) (n=454) compared 3 fixed-doses of
pregabalin (300 mg, 450 mg, or 600 mg, per day) and
alprazolam 1.5 mg/day with placebo, with significantly
greater reductions on the same primary outcome measure
for all four “active” arms: –12.3 with pregabalin 300 mg/
day (p<0.0005 vs placebo), –11.0 with 450 mg/day (p<0.05),
–11.8 with 600 mg/day (p<0.005), and –10.9 with
alprazolam (p<0.05), compared with –8.4 with placebo. In
the second (Montgomery et al 2006) (n=421), 2 doses of
pregabalin (400 mg/day and 600 mg/day) and venlafaxine
(in its immediate release formulation) 75 mg/day were all
significantly superior to placebo (change in HAMA score
from baseline to study end-point: pregabalin 400 mg/day, –
14.7; 600 mg/day, –14.1; venlafaxine, –14.1; placebo, –
11.6). An additional fixed-dose study, without an active
comparator (Pohl et al 2005) (n=341), demonstrated that 3
differing daily dosages of pregabalin (200 mg/day [bid],
400 mg/day [bid], and 450 mg/day [tid]) had similar efficacy,
compared with placebo, the change in HAMA score being
–9.3 with placebo, and –12.4, –12.9, and –12.4 with
pregabalin 200 mg/day, 400 mg/day, and 450 mg/day,
respectively.
A single multi-center, parallel-group, flexible-dose,
randomized, placebo-controlled study in elderly patients (65
years or older, n=273) has been performed (Khan et al 2006).
At study endpoint, pregabalin (mean maximal dose 270 mg/
day) was significantly superior (p<0.05) to placebo, the
change in mean HAMA score from baseline to endpoint
being –12.8 and –10.7, respectively.
The single 6-month relapse-prevention study of
pregabalin (Smith et al 2002) (n=338), in which patientsNeuropsychiatric Disease and Treatment 2007:3(2) 188
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who had responded to 8 weeks of open-label treatment were
randomly allocated to either continue with pregabalin
450 mg/day or to switch to then continue with placebo,
demonstrates that it was superior to placebo (p<0.0001) in
preventing a relapse of anxiety symptoms.
To summarize, 5 out of 6 fixed-dose studies of pregabalin
in the acute treatment of GAD demonstrate that a range of
daily doses (150 mg, 300 mg, 400 mg, 450 mg, and 600 mg)
can be efficacious. The maximum significant difference
between pregabalin (300 mg/day) and placebo on the
primary outcome measure (HAMA) of 3.9 (Rickels et al
2005) is certainly clinically relevant, as is the difference of
3.9 with 600 mg/day (Feltner et al 2003), but in some of the
other studies, the differences between pregabalin and
placebo have uncertain relevance. There is no clear evidence
of a dose-response relationship, and no evidence that
pregabalin is superior in efficacy to 2 commonly used
benzodiazepines. No comparison of pregabalin with an SSRI
appears to have been undertaken, and there is as yet no
evidence of maintenance of effect of pregabalin over periods
longer than 6 weeks, other than in the relapse-prevention
study.
Tolerability of pregabalin
The UK SPC for pregabalin states that it was well tolerated
in clinically relevant doses in conventional safety studies
in animals. An increased incidence of retinal atrophy
commonly observed in aged albino rats was seen after long-
term exposure to doses 5 or more times greater than the
mean human exposure at the maximum recommended dose.
Similarly, the increased incidence of haemangiosarcoma in
mice subject to higher exposures is thought to derive from
platelet changes (and associated endothelial cell
proliferation) that are not present in rats or in humans, based
on short-term and limited long-term clinical data.
Pooled analysis of tolerability data from the six acute
efficacy studies in younger patients suggests that pregabalin
is generally well tolerated (Kavoussi 2006). The most
Table 2 Randomized controlled trials of pregabalin in acute treatment of GAD
Study Treatments N Change in HAMA Responsea (%) 
(LOCF, ITT) (LOCF, ITT) 
Pande et al 2003 Placebo 69 –6.82 28
Pregabalin 150 mg/day 69 –9.24* Not stated. (NS)
Pregabalin 600 mg/day 70 –10.25** 47*
Lorazepam 6 mg/day 68 –11.96*** 57*
Pande et al 2000 Placebo No significant difference in efficacy for any
Pregabalin 150 mg/day treatment versus placebo
Pregabalin 600 mg/day
Lorazepam 6 mg/day
Feltner et al 2003 Placebo 67 –9.27 42.4
Pregabalin 150 mg/day 70 –10.89 47.8
Pregabalin 600 mg/day 66 –13.17** 49.2
Lorazepam 6 mg/day 68 –11.62* 56.3
Rickels et al 2005 Placebo 91 –8.4 31
Pregabalin 300 mg/day 91 –12.2*** 61***
Pregabalin 450 mg/day 90 –11.0* 44
Pregabalin 600 mg/day 89 –11.8** 51**
Alprazolam 1.5 mg/day 93 –10.9* 45*
Montgomery et al 2006 Placebo 101 –11.6 42
Pregabalin 400 mg/day 97 –14.7** 56*
Pregabalin 600 mg/day 110 –14.1* 59*
Venlafaxine 75 mg/day 113 –14.1* 61**
Pohl et al 2005 Placebo 86 –9.3 34
Pregabalin 200 mg/day 78 –12.4** 56**
Pregabalin 400 mg/day 89 –12.9*** 55**
Pregabalin 450 mg/day 88 –12.4** 59**
Khan et al 2006 Placebo 96 –10.7 Not reported
(elderly patients) Pregabalin 150–600 mg/day 177 –12.8 *
(mean maximal 270 mg/day)
aResponse defined as Clinical Global Impression of Improvement score of 1 (“very much improved”) or 2 (“‘much improved”).
*p<0.05, **p<0.01, ***p<0.001, all vs placebo. NS not significant.
Abbreviations: HAMA, Hamilton Rating Scale for Anxiety; ITT-LOCF Intention-to-treat, last-observation-carried forward.Neuropsychiatric Disease and Treatment 2007:3(2) 189
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frequently reported adverse events were dizziness (30%, vs
8% for placebo) and somnolence (29%, vs 11% for placebo).
Both are described as “very common” (i.e., occurring in
more than 1 in 10 patients in the UK SPC for pregabalin),
but in the clinical trial database it was uncommon for patients
to stop double-blind treatment because of these adverse
events (dizziness: pregabalin 3%, somnolence: pregabalin
4%). Across the dose range, study patients dropped out of
treatment with pregabalin or placebo in similar proportions
(11% and 9%, respectively), less so than with the active
comparators (alprazolam 1.5 mg/day, 13%; venlafaxine
75 mg/day, 20%; lorazepam 6 mg/day, 35%). Similar
findings are seen in the single study in the elderly (Khan et
al 2006), in which 10.7% and 9.4% of patients dropped out
due to adverse events with pregabalin and placebo,
respectively.
In the clinical trial database, pregabalin treatment was
not associated with clinically significant effects on heart or
respiratory rate, blood pressure, or changes on the ECG.
Weight gain of clinical significance (>7% increase from
baseline) was more frequent (4%) than with placebo (1.4%).
Overdoses of pregabalin in approximately 100 patients were
not associated with unexpected adverse events or medically
important consequences.
Concerns regarding use of benzodiazepines in the
treatment of patients with anxiety disorders have focused
on their deleterious effects on psychomotor function, the
risk of tolerance during long-term use, and the possibility
of distressing withdrawal symptoms after stopping
treatment. Potential similar concerns regarding pregabalin
have been addressed, to some extent.
Short-term (3-day) placebo-controlled studies of the
effect of pregabalin on cognitive and psychomotor function
in healthy volunteers (n=24) indicate that unlike the
comparator alprazolam (3 mg/day), pregabalin (450 mg/day)
was not associated with significant impairments in
performance in the Hicks Choice Reaction Time Test, the
Sternberg Memory Correct Response Test, or the Brake
Reaction Time Test (Hindmarch et al 2002). The UK SPC
for pregabalin advises that patients should not drive, operate
complex machinery, or engage in other potentially hazardous
activities until they know whether the medication affects
their abilities to perform these tasks. A cross-over
polysomnographic study, again in healthy volunteers,
indicates that both pregabalin and alprazolam significantly
increased total sleep time and sleep efficiency, compared
with placebo, whereas the proportion of slow-wave
(restorative) sleep was significantly increased with
pregabalin, but reduced with alprazolam (Hindmarch et al
2005). No similar studies in clinical samples have been
reported.
Although pre-clinical studies in animal models indicate
that pregabalin has neither a benzodiazepine- or morphine-
like discriminative stimulus, and is not self-administered in
a sustained manner, some evidence of drug “likeability” was
seen in human recreational drug abusers (Kavoussi 2006).
The pooled database provides no evidence of the
development of craving, misuse, or dependence; and an
acute treatment study (Pande et al 2003) showed that
significantly fewer withdrawal symptoms occurred after
stopping pregabalin than did so after stopping lorazepam.
To summarize, analysis of the acute treatment study
pooled database suggests that pregabalin is better tolerated
than some other compounds known to be efficacious in the
treatment of GAD, namely venlafaxine, alprazolam, and
lorazepam. The comparative tolerability of pregabalin and
an efficacious SSRI is not established. The findings of pre-
clinical studies and investigations in non-abusing healthy
volunteers provide some encouragement, but it is currently
uncertain whether problems sometimes seen during longer-
term treatment with benzodiazepines might also occur
during prolonged treatment with pregabalin.
How close is pregabalin to the
“ideal” anxiolytic drug?
When compared with other treatment approaches,
pregabalin could in theory have certain relative advantages,
relating to the speed of onset of efficacy, the breadth of
efficacy, and the absence of particular adverse events seen
during treatment with SSRIs or benzodiazepines. Possible
disadvantages relate to the adverse effects and potential risks
described previously, and to the uncertain efficacy of
pregabalin in relieving depressive symptoms.
Although efficacious in acute treatment of GAD, a few
weeks may pass before SSRIs are associated with a marked
reduction in symptom severity, in contrast to the earlier onset
of action of benzodiazepines. Analyses of the comparator-
controlled studies involving alprazolam or venlafaxine
indicate that pregabalin (across all doses) is associated with
a significantly (p<0.01) greater reduction in symptom
severity, when compared with placebo, after 1 week of
double-blind treatment; this finding is similar to that with
alprazolam, whereas it was seen with venlafaxine after only
2 weeks of treatment (Montgomery et al 2003).
Pregabalin is also significantly superior to placebo in
relieving both the psychic and the somatic symptom clusters,Neuropsychiatric Disease and Treatment 2007:3(2) 190
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as shown through analysis of pooled data from the five
“positive” acute efficacy studies (Lydiard et al 2003). This
result is in contrast to the lack of efficacy of some
benzodiazepines in relieving psychic symptoms, seen in
some studies, and to the relative lack of efficacy of certain
antidepressants in relieving somatic symptoms, seen in
others. A third possible advantage relates to the lack of
adverse events commonly seen during SSRI or venlafaxine
treatment, such as the emergence of sexual dysfunction or
worsened insomnia, but this strength can only be regarded
as potential until a suitable head-to-head comparison with
an SSRI has been performed.
A potential weakness of pregabalin relates to its uncertain
efficacy in reducing depressive symptoms of more than mild
intensity. Although it has been found significantly superior
to placebo in reducing low levels of depressive symptom
severity at baseline in some acute treatment studies (Pande
et al 2003; Pohl et al 2005; Rickels et al 2005), some of this
apparent effect may have been due to reduction in severity
of anxiety and insomnia items included within the Hamilton
Rating Scale for Depression (Hamilton 1960). Furthermore,
patients with more severe depressive symptoms were
excluded from the clinical trial program, and pregabalin has
no demonstrated efficacy in major depression. Most GAD
patients in more routine clinical samples have significant
coexisting depressive symptoms, and recent evidence-based
reviews and treatment guidelines (Baldwin and Polkinghorn
2005; Baldwin et al 2005) have recommended the use of
antidepressants over non-antidepressant anxiolytics, in GAD
patients with coexisting major depressive symptoms.
Conclusions
GAD is common in community and primary care settings,
tends to run a chronic course, and is associated with
significant occupational impairment. However, it is often
not recognized, and even when treated many patients
respond poorly or develop troublesome adverse effects.
Pregabalin appears to have a novel mechanism of action,
and proven efficacy in acute treatment and prevention of
relapse. When compared with some existing
pharmacological treatments, it may offer some advantages,
for example, an earlier onset of clinical effect than that with
venlafaxine, and efficacy across the range of psychological
and somatic symptoms of anxiety. In addition, the existing
clinical trial database indicates that pregabalin is rather better
tolerated than venlafaxine, alprazolam, and lorazepam; and
limited data suggest that the risk of the development of
tolerance or dependence is likely to be lower than that with
benzodiazepines.
It is not yet possible to make a definitive decision
regarding the potential role of pregabalin in the overall
management of patients with GAD. The absence of a
placebo-controlled trial with an SSRI as active comparator
is a major drawback, when considering the relative strengths
and weaknesses of pregabalin compared with existing
treatment approaches. Furthermore, as most patients in
clinical settings have significant co-existing depressive
symptoms, the relative efficacy of pregabalin and an SSRI
or SNRI in treating patients with more than mild depressive
symptoms needs to be established. Finally, the clinical trial
database is too limited to permit more than tentative
conclusions regarding long-term tolerability and patient
acceptability.
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